Akos Czibere

4.5k total citations · 2 hit papers
112 papers, 2.6k citations indexed

About

Akos Czibere is a scholar working on Oncology, Hematology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Akos Czibere has authored 112 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 62 papers in Oncology, 41 papers in Hematology and 35 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Akos Czibere's work include PARP inhibition in cancer therapy (30 papers), Acute Myeloid Leukemia Research (23 papers) and BRCA gene mutations in cancer (15 papers). Akos Czibere is often cited by papers focused on PARP inhibition in cancer therapy (30 papers), Acute Myeloid Leukemia Research (23 papers) and BRCA gene mutations in cancer (15 papers). Akos Czibere collaborates with scholars based in United States, Germany and France. Akos Czibere's co-authors include Rainer Haas, Ingmar Bruns, Guido Kobbe, Roland Fenk, Towia A. Libermann, Fabian Zohren, Luiz F. Zerbini, Ulrich Germing, Thomas Schroeder and Wolf Christian Prall and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Blood.

In The Last Decade

Akos Czibere

111 papers receiving 2.5k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial

2020 252 citations Jennifer K. Litton, Sara A. Hurvitz et al. Annals of Oncology profile →
Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial

2021 183 citations Akos Czibere, Karim Fizazi et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Akos Czibere United States	29	1.2k	1.0k	804	545	344	112	2.6k
Dirk Behringer Germany	27	1.1k 0.9×	630 0.6×	633 0.8×	388 0.7×	204 0.6×	69	2.2k
Hetty E. Carraway United States	35	1.1k 0.9×	1.7k 1.7×	1.4k 1.8×	318 0.6×	399 1.2×	212	3.6k
Gheath Alatrash United States	24	1.8k 1.6×	674 0.7×	646 0.8×	385 0.7×	361 1.0×	126	2.9k
David R. Stover United States	23	1.1k 1.0×	1.4k 1.4×	960 1.2×	372 0.7×	186 0.5×	47	3.0k
Alejandro Martı́n Spain	25	1.4k 1.2×	845 0.8×	909 1.1×	249 0.5×	154 0.4×	128	2.8k
Yuichi Ishikawa Japan	23	476 0.4×	1.4k 1.3×	667 0.8×	472 0.9×	597 1.7×	113	2.5k
Mark N. Kirstein United States	21	1.4k 1.2×	1.4k 1.4×	256 0.3×	1.0k 1.9×	365 1.1×	56	3.4k
Lei Gao China	25	986 0.8×	711 0.7×	667 0.8×	133 0.2×	249 0.7×	170	2.4k
Concetta Conticello Italy	24	1.7k 1.5×	1.4k 1.4×	649 0.8×	270 0.5×	574 1.7×	91	3.0k
Bhagirathbhai Dholaria United States	24	1.6k 1.4×	718 0.7×	754 0.9×	226 0.4×	116 0.3×	139	2.5k

Countries citing papers authored by Akos Czibere

Since Specialization

Citations

This map shows the geographic impact of Akos Czibere's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Akos Czibere with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Akos Czibere more than expected).

Fields of papers citing papers by Akos Czibere

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Akos Czibere. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Akos Czibere. The network helps show where Akos Czibere may publish in the future.

Co-authorship network of co-authors of Akos Czibere

This figure shows the co-authorship network connecting the top 25 collaborators of Akos Czibere. A scholar is included among the top collaborators of Akos Czibere based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Akos Czibere. Akos Czibere is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wang, Diane, et al.. (2024). Impact of Treatment Modality and Route of Administration on Cytokine Release Syndrome in Relapsed or Refractory Multiple Myeloma: A Meta‐Analysis. Clinical Pharmacology & Therapeutics. 115(6). 1258–1268. 4 indexed citations

Elmeliegy, Mohamed, Diane Wang, Wei An, et al.. (2023). Soluble B-Cell Maturation Antigen As a Disease Biomarker in Relapsed or Refractory Multiple Myeloma (RRMM): Evaluation from Elranatamab (ELRA) Magnetismm Studies. Blood. 142(Supplement 1). 3345–3345. 7 indexed citations

Agarwal, Neeraj, Arun Azad, Neal D. Shore, et al.. (2022). Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: TALAPRO-2 phase III study design. Future Oncology. 18(4). 425–436. 41 indexed citations

Litton, Jennifer K., Sara A. Hurvitz, Lida A. Mina, et al.. (2020). Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial. Annals of Oncology. 31(11). 1526–1535. 252 indexed citations breakdown →

Pace, Emily A., Sharlene Adams, Michael D. Curley, et al.. (2018). Dual Inhibition of IGF-1R and ErbB3 Enhances the Activity of Gemcitabine and Nab-Paclitaxel in Preclinical Models of Pancreatic Cancer. Clinical Cancer Research. 24(12). 2873–2885. 44 indexed citations

Sequist, Lecia V., Ian C. Anderson, Todd M. Bauer, et al.. (2016). A phase 2 study of seribantumab (MM-121) in combination with docetaxel or pemetrexed versus docetaxel or pemetrexed alone in patients with heregulin positive (HRG+), locally advanced or metastatic non-small cell lung cancer (NSCLC). Annals of Oncology. 27. vi452–vi452. 3 indexed citations

Denlinger, Crystal S., María Maqueda, David Watkins, et al.. (2016). Randomized phase 2 study of paclitaxel (PTX), trastuzumab (T) with or without MM-111 in HER2 expressing gastroesophageal cancers (GEC).. Journal of Clinical Oncology. 34(15_suppl). 4043–4043. 21 indexed citations

Welner, Robert S., Deepak Bararia, Giovanni Amabile, et al.. (2013). C/EBPα is required for development of dendritic cell progenitors. Blood. 121(20). 4073–4081. 30 indexed citations

Arnedos, Mónica, Crystal S. Denlinger, Wael A. Harb, et al.. (2013). A phase I study of MM-121 in combination with multiple anticancer therapies in patients with advanced solid tumors.. Journal of Clinical Oncology. 31(15_suppl). 2609–2609. 8 indexed citations

10.

Singh, Raminder, Julia Fröbel, Ron‐Patrick Cadeddu, et al.. (2011). The novel compound OSI-461 induces apoptosis and growth arrest in human acute myeloid leukemia cells. Annals of Hematology. 91(2). 173–181. 1 indexed citations

11.

Schroeder, Thomas, Fabian Zohren, Ingmar Bruns, et al.. (2010). Sorafenib Treatment in 13 Patients with Acute Myeloid Leukemia and Activating FLT3 Mutations in Combination with Chemotherapy or as Monotherapy. Acta Haematologica. 124(3). 153–159. 12 indexed citations

12.

Kobbe, Guido, Ingmar Bruns, Thomas Schroeder, et al.. (2010). A 3-day short course of palifermin before HDT reduces toxicity and need for supportive care after autologous blood stem-cell transplantation in patients with multiple myeloma. Annals of Oncology. 21(9). 1898–1904. 19 indexed citations

13.

Czibere, Akos, Ingmar Bruns, Nicolaus Kröger, et al.. (2009). 5-Azacytidine for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome who relapse after allo-SCT: a retrospective analysis. Bone Marrow Transplantation. 45(5). 872–876. 75 indexed citations

14.

Schroeder, Thomas, Ingmar Bruns, Fabian Zohren, et al.. (2009). Clinical Efficacy of Sorafenib in Patients with Acute Myeloid Leukemia (AML) and Activating FLT3-Mutations.. Blood. 114(22). 2057–2057. 5 indexed citations

15.

Hartwig, Sonja, Akos Czibere, Jörg Kotzka, et al.. (2009). Combinatorial hexapeptide ligand libraries (ProteoMiner^™): An innovative fractionation tool for differential quantitative clinical proteomics. Archives of Physiology and Biochemistry. 115(3). 155–160. 51 indexed citations

16.

Aivado, Manuel, Dimitrios Spentzos, Ulrich Germing, et al.. (2007). Serum proteome profiling detects myelodysplastic syndromes and identifies CXC chemokine ligands 4 and 7 as markers for advanced disease. Proceedings of the National Academy of Sciences. 104(4). 1307–1312. 66 indexed citations

17.

Zerbini, Luiz F., Akos Czibere, Yihong Wang, et al.. (2006). A Novel Pathway Involving Melanoma Differentiation Associated Gene-7/Interleukin-24 Mediates Nonsteroidal Anti-inflammatory Drug–Induced Apoptosis and Growth Arrest of Cancer Cells. Cancer Research. 66(24). 11922–11931. 48 indexed citations

18.

Czibere, Akos, Wolf Christian Prall, Luiz F. Zerbini, et al.. (2006). Exisulind induces apoptosis in advanced myelodysplastic syndrome (MDS) and acute myeloid leukaemia/MDS. British Journal of Haematology. 135(3). 355–357. 11 indexed citations

19.

Czibere, Akos, Franck Grall, & Manuel Aivado. (2006). Perspectives of proteomics in acute myeloid leukemia. Expert Review of Anticancer Therapy. 6(11). 1663–1675. 9 indexed citations

20.

Zerbini, Luiz F., Yihong Wang, Akos Czibere, et al.. (2004). NF-κB-mediated repression of growth arrest- and DNA-damage-inducible proteins 45α and γ is essential for cancer cell survival. Proceedings of the National Academy of Sciences. 101(37). 13618–13623. 134 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact